Solidus Biosciences是一家获得STTR第二阶段拨款的公司，其项目名为:开发用于药物发现的先导优化芯片。他们的奖金是根据2009年美国复苏和再投资法案提供的资金，他们的项目将进一步开发和商业化多酶先导优化芯片(Multizyme chip)，用于高通量生成先导化合物类似物，并结合细胞筛选快速识别生物活性衍生物。这种能力直接影响药物发现的一个关键瓶颈;即高效优化先导化合物，开发具有最佳药理性能的药物。Solidus Biosciences, Inc.提出将六种生物催化与药理筛选相结合，以提供针对细胞特异性靶点的生物活性化合物的快速识别，这是先导优化的新范式。此外，Multizyme Chip平台将非常适合于相关行业的先导优化，包括农用化学品、化妆品和药妆。因此，Solidus技术将提高制药、化妆品和化学工业的竞争力和效率，并将成为新的和改进的商业产品的丰富来源。这项研究的更广泛的影响是，Solidus Biosciences将在生产更好、更安全的药物方面取得进展，降低这些药物的开发成本，并提高制药行业的整体效率。Solidus将生产多酶芯片供制药和生物技术公司购买，以促进其先导优化项目，特别是涉及天然产物衍生和复杂合成小分子先导的项目。第二阶段开发的低温保存技术将使第一阶段生产的芯片和芯片处理设备的销售成为可能，并将使Solidus技术平台无缝渗透到公司的目标市场。 Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

NeuroGenomeX是一家研发治疗大脑和神经系统疾病的药物的公司。目前的NeuroGenomeX发现项目专注于癫痫和创伤性脑损伤的治疗靶点。NeuroGenomeX正在开发其主要候选药物2-脱氧-d -葡萄糖(2DG)，作为一种抗惊厥药，可以阻止癫痫发作，并对癫痫的长期不良后果具有有益作用。2DG在创伤性脑损伤(TBI)动物模型中也显示出良好的神经保护作用。

SynDevRx开发了一种利用共轭技术提高小分子药物活性和安全性的技术。该公司的技术通过在疾病部位集中活性来提高药物的治疗指数。它提供了可预测和可靠的物理性质的小分子，可以加快开发时间和降低成本，同时提高PK配置。SynDevRx的主要候选药物SDX-7320针对肿瘤市场，抑制MetAP2 -一种酶，独立研究表明它是肿瘤生长、增殖和转移的关键。

科诺瓦提供抗肥胖药物研发

Allozyne是一家蛋白质优化公司，致力于开发改进的生物疗法，以治疗多个领域未满足的医疗需求。Allozyne的两个技术平台可以在任何特定位置将氨基酸类似物整合到现有的生物制剂中，从而提高药效、耐受性和药理学。

Optimata Ltd.是一家以科学为基础的跨学科私营公司，从事优化药物治疗方案的生物模拟技术。Optimata与制药和生物技术公司合作，通过模拟疾病过程开发有效的疾病新疗法。这旨在缩短上市时间和开发成本，同时提高新开发药物的竞争力。